In accordance with the commitments it made in 2021, France has delivered 10 million doses of AstraZeneca and Pfizer vaccine against Covid-19 to African Union countries. These donations are all the more critical as a new wave of pandemic is to be feared on the continent.
Since the start of the pandemic, France has promoted equitable and universal access to vaccines, particularly in Africa. Strongly committed to accelerating vaccination worldwide, it will have donated 120 million doses of vaccine by summer 2022, of which 73 million are already available.
Vaccines are allocated and distributed through a partnership with the African Vaccination Acquisition Trust (AVAT) and the COVAX mechanism to provide global access to the vaccine coordinated by Gavi, the Global Alliance for Vaccines and Immunization.
France wanted this action to benefit African countries as a priority. Mauritania received its first donation via COVAX last April. Since then, nearly 60% of French donations have been allocated to 38 African countries as the doses purchased by France become available.
This effort by France represents a first step – decisive but not yet sufficient – to bridge the gap in access to health products between Africa and developed countries in the fight against the Covid-19 pandemic. In addition to donations that help accelerate vaccination in the field, our common goal is to help build production capacities in Africa, thus enabling it to respond in a sovereign way to future pandemic epidemics.
With its EU partners, France supports the ambition of African nations to build a pharmaceutical industry on the continent. She is actively engaged in building vaccine production capacities in Africa and actively contributes to the transfer of messenger RNA technology to the African continent, particularly South Africa, Rwanda and Senegal.